Notice of Intent to Publish a Funding Opportunity Announcement for Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)

0
358

Opportunity ID: 324261
Opportunity Number: NOT-NS-20-033
Opportunity Title: Notice of Intent to Publish a Funding Opportunity Announcement for Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Health
Category Explanation:
CFDA Number(s):
Eligible Applicants: State governments
County governments
Independent school districts
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Small businesses
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Additional Information on Eligibility:
Agency Code: HHS-NIH11
Agency Name: Department of Health and Human Services
National Institutes of Health
Posted Date: Feb 05, 2020
Last Updated Date: Feb 05, 2020
Estimated Synopsis Post Date: Feb 11, 2020
Fiscal Year: 2021
Award Ceiling:
Award Floor:
Estimated Total Program Funding:
Expected Number of Awards:
Description: The NIH announces its intention to reissue PAR-18-546 for investigators seeking support from the Blueprint Neurotherapeutics (BPN) Network. Applicants will be encouraged to utilize a customized set of contract resources, and consultants from the BPN Network to help advance their neuroscience-focused drug discovery and development projects into the clinic. This Notice is provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. This FOA will utilize the UG3/UH3 activity code. Details of the planned FOA are provided below. The FOA is expected to be published in February of 2020 with an expected application due date in August 2020.
Version: 1





Visit the Official Webpage For More Details on Notice of Intent to Publish a Funding Opportunity Announcement for Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)